Wei Kang was sitting in his office, looking at the freshly released financial reports.
Last year's financial report came out relatively late, not reaching his desk until the end of January.
The overall performance in the sixth year is quite gratifying, and it still maintains rapid growth, with revenue exceeding the 70 billion mark, reaching US$78.2 billion.
Compared with the previous year, the performance growth point is mainly in the field of medical equipment, which can be said to be a rapid improvement and extremely eye-catching.
Portable color ultrasound, portable medical kits, and capsule gastroenteroscopy are very popular in China and are also highly sought after abroad, contributing to a lot of sales.
This does not include artificial blood and nano-pills. Once these two are launched, the performance this year will definitely hit a new high.
If we can win the market in the field of endoscopy, Sanqing's equipment business will be completely established.
Wei Kang looked at the pharmaceutical business data and frowned.
As he expected, the sales growth of HIV treatment drugs has disappeared and is expected to gradually decline starting next year.
After all HIV-infected patients in China have been cured, the only ones that can still support sales are overseas developed countries.
After all HIV patients in Eagle Country and Europa are cured, this former anti-AIDS king will surely go downhill.
In two or three years, I am afraid it will become a niche and unpopular drug and will no longer be able to bring much revenue to the company.
The only remaining achievement in the anti-AIDS field is Ailin. The price of this drug has been greatly reduced, so it has become the first choice treatment drug for AIDS patients in many developing countries.
Seeing such a result, Wei Kang couldn't help but smile bitterly.
Sure enough, developing such a drug that can completely cure the disease with one shot is simply digging your own grave. No wonder major pharmaceutical companies are unwilling to do such stupid things anymore. Instead, they are developing antihypertensive drugs and hypoglycemic drugs that require long-term treatment. Medications taken.
Drugs that continuously bring revenue to pharmaceutical companies are the real cash cows and trump cards.
Even if their effects are not that good and they cannot cure the patient, but can only control the disease, they can keep the patient's wallet open and continue to lose money.
Although it is a trickle, it can still gather into rivers and seas, filling the coffers of pharmaceutical companies.
Rather than like now, it breaks out for two or three years, then cuts off in half and disappears quickly.
Sanqing is now facing the same situation as Gilead back then.
The drug he invented was so effective that it eliminated patients so cleanly that it indirectly killed his own business.
In fact, most pharmaceutical companies with a single product range face this dilemma.
Even pharmaceutical giants like Pfizer, Bayer, and Novartis still have the same troubles.
Unlike Gilead, pharmaceutical giants and small and medium-sized pharmaceutical companies are worried about the expiration of patented drugs.
No matter how effective or awesome a drug is, it only has a 20-year patent. When the patent expires, pharmaceutical companies will make less and less profits.
If there are no new top drugs, pharmaceutical companies will lose their previous leading position, and even completely lose this market under the impact of generic drugs.
The research and development of new drugs is extremely difficult, and this is how many pharmaceutical companies have declined.
The pharmaceutical giants’ solution to this problem is to buy, buy, buy.
Spend hundreds of millions or billions to buy promising new drug projects, complete clinical trials, and launch them on the market to create new trump drugs.
Anyway, they have a lot of money and they can cut corners everywhere. As long as they buy a few more pipelines, they will always occupy a lot of holes.
Fortunately, Sanqing is not Gilead, and it does not rely solely on this flagship drug to survive.
Nor is it Pfizer, which relies on its ability to generate cash to continue its glory.
Anti-AIDS drugs are only one of Sanqing’s many original drugs, which is why Weikang has the confidence to bring them to the market.
Instead of anti-AIDS drugs, Sanqing also has anti-cancer drugs, anti-AD drugs, and a series of new drugs.
As long as a steady stream of new drugs are released every year, Sanqing will be able to maintain its current momentum and move forward at full speed on track.
Years of investment in research and development have now begun to bear fruit.
Sanqing’s current independent research and development capabilities are also very strong, and it can develop several original new drugs every year.
Therefore, Wei Kang is confident and feels that he will definitely not fall into the situation of Gilead.
When he thought of Gilead, he immediately pulled out the latest quarterly financial reports of major pharmaceutical giants.
"Haha, it turns out that Gilead's anti-AIDS drug market is also shrinking, even faster than Sanqing."
Looking at his opponent's quarterly report, Wei Kang couldn't help laughing.
"It seems that if we can't turn around on hepatitis B drugs, I'm afraid the name Gilead will soon fall out of the top 20 and become unknown."
"I hope they can find a new flashpoint."
Wei Kang shook his head. This is really a matter of success and failure. With only one or two trump cards, even if the market share reaches 60% or 80%, so what?
When patients are cured, pharmaceutical companies will disappear.
As a pharmaceutical company, he understands better than anyone else the principle of failure to advance or retreat.
Only by continuous innovation and advancement can we survive in this cruel market and continue to capture excess profits.
But this is also related to Gilead’s area of expertise.
Antiviral drugs are very different from other drugs in that they deal with microorganisms such as viruses.
Like antibiotics and the immune system, they are engaged in a life-or-death battle with their invading opponents, and the final winner must be determined.
The two simply cannot coexist peacefully and live together under the same roof.
Drugs used to treat diabetes are a supplement to the insulin that the body lacks. Just like eating and drinking water, they need to be taken in continuously to maintain the balance of the body's basic functions.
Obviously, in the eyes of pharmaceutical companies, the latter is a good and sustainable business.
Wei Kang continued to look through the quarterly reports of Johnson & Johnson and Pfizer, and soon a joyful smile appeared on his face.
"Finally surpassed Pfizer." He clenched his fists and waved them in the air in excitement.
"If there are no surprises, Sanqing's revenue last year should be the second in the pharmaceutical industry, second only to Johnson & Johnson."
"Of course, this includes the revenue of Sanqing's device business. If we only compare the revenue of drugs, it is still not as good as Pfizer."
"It's not a big problem. Sanqing is also constantly launching new drugs and will soon completely surpass Pfizer in the pharmaceutical field."
"In the sixth year, Sanqing finally reached the second place in the world. We can look forward to the future."
Thinking of this, Wei Kang couldn't help laughing.
He lay back casually and leaned on the soft and thick back of the chair. His whole body relaxed and his expression became leisurely and comfortable.
"Actually, champions are nothing more than that. They just rely on years of accumulation to become too big to fail. In the past few years, Johnson & Johnson has been resting on its laurels. There are no breakthrough results in the pharmaceutical and device fields. Haha, for Sanqing, it is completely Vulnerable.”
"Next year, Sanqing will gain a firm foothold in the equipment field. With a two-pronged approach, it will definitely defeat Johnson & Johnson and reach the top of the championship."
"At that time, the entire medical world will be dominated by Sanqing."
"The progress of human medical technology will be led by Sanqing."
Today is New Year's Eve. I will do housework during the day and watch the Spring Festival Gala with my parents at night. I will only update 2,000 words.
I wish you all a happy New Year and good luck in the Year of the Rabbit. Happy New Year to everyone!
(End of chapter)
